'Novel' oral iron drug accepted for review in Europe
This article was originally published in Scrip
Shield Therapeutics has had its European filing for a novel oral iron replacement drug accepted for review by the EMA. Feraccru (ST10, ferric maltol), for the treatment for iron deficiency anemia (IDA) in patients with inflammatory bowel disease (IBD) and those intolerant of oral ferrous therapies – has been developed as an alternative for those patients whose only current option is intravenous iron therapy.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.